Biotricity Q1 revenue $1.76M, up 290% YoY, 9th consecutive triple-digit growth quarter

BIOTRICITY INC.

Revenue $1.76M for Q1 FY2022, up 290% vs. Q1 FY2021; sequential growth 49%.
Operating expenses $4.2M, up only 17% YoY; R&D spend $590K, up 39%.
Company projects continued revenue growth into FY2023; awaiting FDA approval for Biotres holter product.
Gross margin or net income figures not disclosed; Company remains early-stage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.